Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05352321
NA

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined surgery could bring patients better local-regional control and lower adverse reactions.

Official title: Multicenter Randomized Controlled Trial of Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

264

Start Date

2022-06-01

Completion Date

2028-06-01

Last Updated

2022-07-01

Healthy Volunteers

No

Interventions

DRUG

Gemcitabine

for induction chemotherapy

DRUG

Cisplatin

for induction and concurrent chemotherapy

RADIATION

regular intensity-modulated radiotherapy

in active comparator arm

PROCEDURE

surgery

in experimental arm

RADIATION

Target-reduction intensity-modulated radiotherapy

in experimental arm

Locations (2)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Fifth Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China